Verdad Advisers’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Verdad Advisers's CGEM Position: Q3 2026 in Review
Verdad Advisers sold out of Cullinan Therapeutics (CGEM) in Q3 2026, closing a stake of 28,987 shares — an estimated $528K sold.
Verdad Advisers first reported a position in CGEM in Q1 2026 and held it in 2 quarters. The position peaked at $528K in Q2 2026. 180 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Verdad Advisers reported no remaining Cullinan Therapeutics position as of Q3 2026 after selling out during the quarter.
- Verdad Advisers sold 28,987 Cullinan Therapeutics shares in Q3 2026, an estimated $528K.
- Verdad Advisers first reported a position in Cullinan Therapeutics in Q1 2026 and held it in 2 quarters.
- Verdad Advisers's Cullinan Therapeutics position peaked at $528K in Q2 2026.
- 180 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.